Answers are grounded in this paper and cite their sources.
vg. Flow cytometry was performed to assess the dose-dependent transduction specificity and efficiency of AAV-LungM3 in type I alveolar epithelial cells (AT1 cells) and type II alveolar epithelial cells (AT2 cells). Using the favorable dose determined by the dose-response assay, the temporal changes in AT2 cell transduction specificity and efficiency were further monitored over a 4-week period. In addition, hematoxylin and eosin (H&E) staining, detection of peripheral blood inflammatory factors, and analysis of plasma biochemical indicators were used to evaluate early-phase safety. In vitro transduction increased in a dose-dependent manner. In vivo assays revealed that the AT2 cell transduction specificity of AAV-LungM3 decreased gradually with increasing viral dose, whereas its transduction specificity for AT1 cells increased. Nevertheless, no significant differences in the transduction efficiency of AT1 cells and AT2 cells were observed among all dose groups. Longitudinal monitoring indicated that week 2 was the preferred time point for AAV-LungM3 transduction. In conclusion, under the tested conditions, AAV-LungM3 exhibited targeting specificity to AT2 cells and favorable in vivo expression with no observed toxic effects, serving as a potential delivery platform for pulmonary gene therapy.
No takes yet. Share an insight, caveat, or question.
Nie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: